Proteins and Peptides
14 March 2017
Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand4 March 2017
FDA approves first treatment for frequent urination at night due to overproduction of urine28 February 2017
RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.28 February 2017
La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-50121 February 2017
CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates20 February 2017
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada16 February 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Pegfilgrastim for Review16 February 2017
Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery16 February 2017
Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 20178 February 2017
Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome5 February 2017
Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 DiabetesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports